For many years, cancer research has focused on the adult stem cells present in malignant tumors. It is believed that current cancer treatments sometimes fail because they do not target these cells. According to classic models of carcinogenesis, these events can occur in any cell. In contrast, the cancer stem cell (CSC) hypothesis states that the preferential targets of oncogenic transformation are tissue stem cells or early progenitor cells that have acquired the potential for self-renewal. These tumor-initiating cells, or CSCs, in turn, are characterized by their ability to undergo self-renewal, a process that drives tumorigenesis and differentiation, which contributes to the cellular heterogeneity of tumors. Herein, we discuss the definitions and properties of CSCs in the major human cancers.
BACKGROUND AND DEFINITIONS
lapse and metastasis. Therefore, the development of specific therapies targeted at CSCs could improve the survival and quality of life of cancer patients, especially in Stem cells are found in many different somatic tissues and are important participants in their physiology cases of patients with metastatic disease. The first conclusive evidence for the existence of ( Fig. 1 ). Stem cells have three distinctive properties: (a) self-renewal, (b) the capability to develop into multiple CSCs was reported in 1997. Bonnet and Dick (5) isolated a subpopulation of leukemic cells that expressed lineages, and (c) the potential to extensively proliferate. The combination of these three properties makes stem the CD34 surface marker, but lacked the CD38 marker. This CD34 + /CD38 − subpopulation was capable of initiat-cells unique. The attribute of self-renewal is especially notable because its subversion is highly relevant to on-ing tumors that were histologically similar to the donor in NOD/SCID mice (48) . cogenesis and malignancy (1, 57) . Aberrantly increased self-renewal, in combination with the intrinsic growth In cancer research experiments, tumors can be established by the injection of tumor cells into an experimen-potential of stem cells, may account for much of what is considered a malignant phenotype. tal animal. Disease progression is then followed over time, and novel drugs can be tested for their ability to CSCs are found in tumors or hematological cancers and possess characteristics associated with normal stem inhibit tumor growth; however, efficient tumor formation requires the introduction of thousands or tens of cells, specifically the ability to give rise to all cell types found in a particular cancer sample; therefore, these thousands of cells. Traditionally, this feature has been explained by poor methodology (i.e., the tumor cells cells are tumorigenic, in contrast to other nontumorigenic cancer cells. CSCs may generate tumors through lose their viability during transfer) or the critical importance of the tumor microenvironment (i.e., the particular the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are proposed to biochemical surroundings of the injected cells). Supporters of the CSC paradigm argue that only a small fraction persist in tumors as a distinct population and cause re- of the injected cells, the CSCs, have the potential to gen-the past several decades, many of the physical, biological, and developmental features of normal hematopoietic erate a tumor. In human acute myeloid leukemia (AML), the frequency of these cells is less than 1 in 10,000 (5). stem cells have been defined (41, 63) , and useful methods for studying stem cells in almost any context have Further evidence for this hypothesis has been provided by histological studies of tumors. Many tumors been established (49) . Hematopoietic cell cancers, such as leukemia, are clearly different from solid tumors, but are heterogeneous and contain multiple cell types native to the host organ. Heterogeneity is commonly retained certain aspects of hematopoietic stem cell biology are relevant to our understanding of the broad principles of during the metastasis of tumors. This implies that the cell that produced them had the capacity to generate CSC biology (57) . CSCs have been unequivocally identified in various types of leukemia, and several biologic multiple cell types; that is, it possessed multidifferentiation potential, a classical hallmark of stem cells (5).
properties of these stem cells have direct implications for therapy (21, 30, 37, 69) . The identification of leukemic stem cells prompted further research into other types of cancer, leading to the CSCs are readily evident in chronic myelogenous leukemia (CML) (34) and acute myelogenous leukemia identification of CSCs in several solid tumors, including cancers of the brain (64), breast (2), lung (40) , colon (AML) (5,43), and they have also been implicated in acute lymphoblastic leukemia (ALL) (8,13,16). CML (53,55), ovary (72), pancreas (45) , and prostate (42, 47) .
stem cells have a well-described stem cell phenotype and a quiescent cell cycle status. Similarly, AML stem CANCER STEM CELLS IN THE cells are mostly quiescent (29, 31, 33, 67) , suggesting that HEMATOPOIETIC SYSTEM conventional antiproliferative cytotoxic regimens are unlikely to be effective against them. AML stem cells have The hematopoietic system is the best characterized somatic tissue with respect to stem cell biology. Over surface markers, such as the interleukin-3 receptor α chain, that are not present on normal stem cells (36) . neural stem cells, in that it expressed CD133 and nestin, and was the same in patients with the same pathological These markers may be useful for antibody-based (38) or other related therapeutic regimens (6, 26) . Early efforts type of tumor and in patients with different pathological subtypes. This suggests that brain tumors with a very have demonstrated the usefulness of antibodies against the CD33 antigen in the treatment of AML (32, 44) , and similar phenotype can be generated from BTSCs. Further cellular and molecular studies of BTSCs would be recent reports indicate that CD33 is expressed on some leukemic stem cells (66) . These observations warrant the required for better understanding of brain tumor biology. Comparison of normal neural stem cells and BTSCs will continued development of immunotherapy strategies against stem cell-specific antigens.
aid in finding the normal brain cell that is the source of the tumor.
CANCER STEM CELLS IN THE BRAIN
CANCER STEM CELLS IN THE BREAST Brain tumors are the leading cause of cancer mortality in children and are difficult to treat despite advances Breast CSCs have been definitively identified by Al-Hajj et al. in specimens from patients with advanced in surgery and adjuvant therapy. Most current brain tumor research is focused on the molecular and cellular stages of metastatic breast cancer. They demonstrated that cells with a specific cell-surface antigen profile analysis of the tumor mass. Brain tumors are typically comprised of morphologically diverse cells that express (CD44 + /CD24 − ) could successfully establish themselves as tumor xenografts (2). Recent studies have provided a variety of neural lineage markers. Analysis of the basic morphology and phenotype of brain tumors has yielded definitive evidence for the existence of CSC populations within breast cancer cell lines. Charafe-Jauffret et al. a limited amount of knowledge with respect to the clinical behavior of the tumor, as brain tumors that share a used 33 cell lines derived from human breast cancers and nontransformed breast cells to study the expression similar morphology and phenotype can have a very different prognosis and response to treatment.
of the stem cell marker aldehyde dehydrogenase (ALDH) (9). ALDH is a detoxifying enzyme that oxidizes intra-The determination of key cells in the tumor population that maintain the tumor will provide an insight into cellular aldehydes, and it is thought to play a role in the differentiation of stem cells via the metabolism of retinal the mechanism of brain tumorigenesis and allow us to identify the cell of origin in the normal brain. There is to retinoic acid (11) . ALDH activity, as assessed by the fluorescent ALDEFLUOR assay, has been successfully overwhelming evidence in other malignancies, such as leukemia, that the clonal population of neoplastic cells used to isolate CSCs from multiple myeloma and acute myeloid leukemia as well as from brain tumors (10, 15) . exhibits marked heterogeneity with respect to proliferation and differentiation (5,61). Rare stem cells within ALDH activity can be used to isolate a subpopulation of cells that display stem cell properties from normal hu-the leukemic population possess extensive proliferative and self-renewal capacities that are not observed in the man breast tissue and breast carcinomas (27). The majority of breast cancer cell lines contain an ALDE majority of leukemic cells. Fractionation and functional analysis of leukemic stem cells indicated that they are FLUOR-positive population with a distinct molecular profile that displays CSC properties (9). These studies necessary and sufficient to induce leukemia (5,43).
We have isolated normal neural stem cells in culture have important implications for the interpretation of data using cell lines and suggest that these lines may be use-(as clonally derived neurospheres, each of which arise from a single stem cell) for the analysis of human pedi-ful for elucidating the regulatory pathways of CSCs. atric brain tumors (62). Analysis of neurosphere cells CANCER STEM CELLS IN THE LUNG were used to functionally characterize the populations of tumor cells. We purified and characterized a cell from Bronchoalveolar stem cells (BASCs), which may be precursors of lung adenocarcinoma, have been identified primary human brain tumors with different phenotypes; this cell type had a marked capacity for proliferation, using a mice model for lung cancer (40) . BASCs were resistant to bronchiolar and alveolar damage and prolif-self-renewal, and differentiation. This cell represented a minority of the tumor cell population and was identified erated during epithelial cell renewal in vivo. BASCs exhibited self-renewal and were multipotent in clonal by the expression of the cell surface marker CD133. This CD133 + cell, which we have termed the brain tu-assays, highlighting their stem cell properties (3); furthermore, BASCs expanded in response to oncogenic K-mor stem cell (BTSC) (43) , lacked the expression of neural differentiation markers and was necessary for the ras in vitro and in lung tumor precursors in vivo (35). These data support the hypothesis that BASCs are a proliferation and self-renewal of the tumor in culture. This cell was also capable of differentiating in vitro into stem cell population that maintains the bronchiolar Clara cells and alveolar cells of the distal lung and that their the cell types found in the tumor in situ. The marker phenotype of the BTSC was similar to that of normal transformed counterparts give rise to adenocarcinomas.
116 CHEN ET AL.
The K-ras, phosphatase and tensin homolog (Pten), (14, 19, 45, 59) was observed in these cultured murine cells. phosphoinositide 3-kinase (PI3K), and cyclin-dependent kinase pathways have been implicated in the prolifera-CANCER STEM CELLS IN THE PANCREAS tion of these stem cells (70, 71) . The potential role of bronchoalveolar stem cells and other tumorigenic stem Al-Hajj et al.
(2) reported that a phenotypically distinct and relatively rare population of CD44 + /CD24 − /epi-cell populations in the development and prognosis of human lung cancer and its resistance to drugs is an im-thelial-specific antigen-positive (ESA + ) tumor-initiating cells was responsible for the propagation of human met-portant area for future investigation.
astatic breast cancer specimens in NOD/SCID mice.
Li et al. identified a highly tumorigenic subpopulation of CANCER STEM CELLS IN THE COLON
CD44 + /CD24 + /ESA + pancreatic cancer cells in a xeno-Colon cancer is one of the best understood neoplasms graft model of primary human pancreatic adenocarcinofrom a genetic perspective (24, 25, 60) , yet it remains the mas grown in immunocompromised mice (45) . CD44 + / second most common cause of cancer-related death, in-CD24 + /ESA + pancreatic cancer cells (0.2-0.8% of pandicating that some of its cancer cells are not eradicated creatic cancer cells) had a 100-fold increased tumoriby current therapies (54, 56 ). It has not been established genic potential when compared to nontumorigenic canwhether every colon cancer cell possesses the potential cer cells. Fifty percent of animals injected with 100 to initiate and sustain tumor growth, or whether the tu-CD44 + /CD24 + /ESA + cells formed tumors that were hismor is hierarchically organized so that only a subset of tologically indistinguishable from the human tumors cells (i.e., CSCs) possess such a potential (22, 39, 69) . from which they were derived. The enhanced ability of O'Brien et al. (55) used renal capsule transplantation in CD44 + /CD24 + /ESA + pancreatic cancer cells to form tunon-obese diabetic (NOD)/severe combined immunodemors was confirmed in an orthotopic pancreatic tail ficient (SCID) to identify a human colon cancer-initiatinjection model. The CD44 + /CD24 + /ESA + pancreatic ing cell (CC-IC). Purification experiments established cancer cells possessed the stem cell properties of selfthat all CC-ICs were CD133 + ; the CD133 + cells, which renewal, the ability to produce differentiated progeny, comprised the majority of the tumor, were unable to iniand the increased expression of the developmental sigtiate tumor growth. CC-ICs within the CD133 + populanaling molecule sonic hedgehog (SHH). The identification were able to maintain themselves, differentiate, and tion of pancreatic CSCs and the elucidation of the sigreestablish tumor heterogeneity after serial transplantanaling pathways that regulate their growth and survival tion. The identification of CSCs in the colon, which are may provide novel therapeutic approaches to treat pandistinct from the bulk of tumor cells, provides strong creatic cancer, which is notoriously resistant to standard support for the hierarchical organization of human colon chemotherapy and radiation. cancer. Their existence suggests that for therapeutic strategies to be effective, they must target the CSCs.
CANCER STEM CELLS IN THE PROSTATE
The cellular origins of prostate cancer are still unde-
CANCER STEM CELLS IN THE OVARY
cided. It has been suggested that prostate cancers arise from terminally differentiated luminal cells (20, 51) be-In ovarian cancer, Bapat et al. (4) isolated two clones from patients' ascites that could organize anchorage-cause the bulk population of tumor cells, in the most common form of prostate cancer, express luminal cell-independent, spherical structures (spheroids) in vitro, similar to those observed in ascites in vivo (7). These specific markers (cytokeratins (CK) 8 and 18, androgen receptor (AR), prostate-specific antigen (PSA), and clones formed xenografts in nude mice (with a histopathology similar to the parental human tumors), serially prostatic acid phosphatase (PAP)), but lack the expression of basal cell markers, such as p63. Moreover, cells propagated in animals (4), and expressed the stem cell factor receptor CD117 (c-kit)-a well-known proto-that solely express basal cell markers, such as CK5 and CK14, are rarely observed. This has led to the specula-oncoprotein (52) . Another ovarian cancer study identified a subpopulation of dye-excluding cultured murine tion that prostate cancers are derived from intermediate progenitors that have acquired the ability for self-renewal cells, representing membrane transporter-expressing putative stem cells, that were highly tumorigenic in mice (68) . Several lines of evidence support the hypothesis that when compared to dye-staining (i.e., non-effluxing) cells (65) . To satisfy the CSCs' criterion of distinctive cell prostate cancer stem cells arise from normal stem cells. Advanced prostate cancers are androgen independent surface markers (18), the expression of CD117 (similar to the ascites study) and the hyaluronate receptor CD44 and basal cells can be phenotypically identified in the majority of metastases (46) . Craft et al. showed that ad-(also a marker for CSCs from several other solid tumors vanced androgen-independent tumors arise from the creatic cancer, still have dismal survival rates. Other cancers, such as head and neck cancers, are often resis-clonal expansion of AR − cells that are present at a frequency of 1/10 5 -10 6 AR + cells (17) . Recent studies have tant to current therapies, making less-invasive treatments more difficult. In addition, current chemotherapeutic found that only the most primitive cells (α2β1 hi /CD133 + / CD44 + ), which were phenotypically identical to normal regimens cause severe side effects because they target all rapidly dividing cells. prostate stem cells, could self-renew in vitro (14) . Under differentiating conditions, AR + /PAP + /CK18 + luminal Existing cancer treatments have mostly been developed using animal models, where therapies that were cells could be identified in these cultures, suggesting that they were derived from the more primitive cell pop-able to promote tumor shrinkage were deemed effective. However, animals do not provide a complete model of ulation. In support of this finding, the CD44 + population from xenograft tumors and cell lines had enhanced pro-human disease. Tumor relapse is exceptionally difficult to study in mice because they have a short life span that liferative potential and tumor-initiating ability in vivo compared to CD44 + cells (58) . The CD44 + cells were does not usually exceed 2 years. The study of CSCs is still in its early stages, primarily taking place in the labo-AR − and expressed higher mRNA levels of "stemness" genes, such as OCT3/4 and BMI1. By using clonally ratory. No standard treatments have yet been developed as a result of research on CSCs. The next step is to derived human prostate cancer epithelial cells expressing human telomerase reverse transcriptase (hTERT), understand CSC activity and to identify drugs that target the stem cells without harming normal cells. Treatments Gu et al. demonstrated that these lines could regenerate tumors in mice that resembled the original tumor (with that specifically target CSCs would cause fewer side effects for patients. respect to the Gleason score) in patients (28) . The tumors contained luminal, basal, and neuroendocrine cells, REFERENCES implying that the clone of origin could differentiate into the epithelial cell lineages of the prostate. In this case, creas, prostate, and colon cancers) (14, 19, 23, 40, 45, 59) . 
